A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Gdansk, 80-546, Germany
Belgavi, Karnataka 590001, India
Yoshinogari-cho, Kanzaki-gun, Saga-ken 842-0192, Japan
Yokohama, Kanagawa, 213-8507, Japan